Hypercoagulability: Interaction between inflammation and coagulation in familial Mediterranean fever

Clinical Rheumatology

Volumn 26, Issue 3, 2007, Pages 366-370

  Aksu, Guzide ^a,b   Ozturk, Can ^a   Kavakli, Kaan ^a   Genel, Ferah ^a   Kutukculer, Necil ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Familial mediterranean fever; Hypercoagulability; Inflammation

Indexed keywords

ACTIVATED PROTEIN C; ACUTE PHASE PROTEIN; ANTICOAGULANT AGENT; ANTITHROMBIN; CARDIOLIPIN ANTIBODY; COLCHICINE; D DIMER; LUPUS ANTICOAGULANT; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBIN ANTITHROMBIN COMPLEX;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ARTICLE; AUTOIMMUNITY; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTHROMBIN TIME; STREPTOLYSIN TITER; THROMBIN TIME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HEMOSTASIS; HUMANS; INFLAMMATION; MALE; PROTEIN C DEFICIENCY; PROTHROMBIN; PROTHROMBIN TIME; THROMBIN TIME; THROMBOPHILIA;

EID: 33947633503     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0334-y     Document Type: Article

References (30)

1. The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797-807
2. The French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25-31
3. Kastner DL (1998) FMF: The genetics of inflammation. Hosp Prac 33:131-158
4. Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R, Kastner DL (1998) FMF at the millennium: Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 77:268-297
5. McDermott MF, Aksentijevich I (2002) The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol 2:511-516
6. Ozen S (1999) Vasculopathy, Behcet's syndrome, and familial Mediterranean fever. Curr Opin Rheumatol 11:393-398
7. Yalcinkaya F, Ince E, Ucar T, Ozkaya N, Tekin M, Elhan AH, Tutar E, Guriz DH, Aysev D, Gokdemir R, Dogru U, Tumer N (2002) Antistreptococcal response is exaggerated in children with familial Mediterranean fever. Clin Rheumatol 21:378-381
8. Tekin M, Yalcinkaya F, Tumer N, Cakar N, Kocak H (1999) Familial Mediterranean fever and acute rheumatic fever: A pathogenetic relationship? Clin Rheumatol 18:446-449
9. Bauer KA (2003) Management of thrombophilia. J Thromb Haemost 1:1429-1434
10. Gathof BS, Picker SM, Rojo J (2004) Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 9:95-103
11. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, Degen JL (2004) Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest113:1596-1606
12. Esmon CT (2004) Crosstalk between inflammation and thrombosis. Maturitas 47:305-314
13. Opal SM (2003) Interactions between coagulation and inflammation. Scand J Infect Dis 35:545-554
14. Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51-56
15. Gil W (2001) Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation. Perfusion 16:27-35
16. Hooper WC, Phillips DJ, Renshaw MA, Evatt BL, Benson JM (1998) The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J Immunol 161:2567-2573
17. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L (1998) Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 160:5130-5135
18. Drake WT, Lopes NN, Fenton JW 2nd, Issekutz AC (1992) Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. Lab Invest 67:617-627
19. Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Bassoy Y, Yilmaz E (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509-514
20. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879-1885
21. Ruiz N, Wang B, Pentland A, Caparon M (1998) Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci. Mol Microbiol 2:337-346
22. Fukumori T, Ohta H, Okubo A, Hino M, Ohta K, Yamane T, Tatsumi N (2002) New compact-type latex photometric immunoassay system for hemoglobin and three acute inflammation markers: Neutrophil count, C-reactive protein, and anti-streptolysin O. J Clin Lab Anal 16:95-102
23. Stassen M, Muller C, Richter C, Neudorfl C, Hultner L, Bhakdi S, Walev I, Schmitt E (2003) The streptococcal exotoxin streptolysin O activates mast cells to produce tumor necrosis factor alpha by p38 mitogen-activated protein kinase- and protein kinase C-dependent pathways. Infect Immun 71:6171-6177
24. Courillon-Mallet A, Bevilacqua M, Wautier JL, Dervichian M, Cattan D, Caen J (1986) Increased procoagulant response of monocytes from patients with familial Mediterranean fever. Thromb Haemost 56:211-213
25. Mosesson MW, Wautier JL, Amrani DL, Dervichian M, Cattan D (1982) Evidence for circulating fibrin in familial Mediterranean fever. J Lab Clin Med 99:559-567
26. Disdier P, Swiader L, Aillaud MF, Harle JR, Weiller PJ (1996) Familial Mediterranean fever crisis and lupus anticoagulant. Lancet 348:1321-1322
27. Greaves M, Cohen H, MacHin SJ, Mackie I (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109:704-715
28. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, O'Shea JJ, Rosenberg HF, Malech HL, Kastner DL (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95:3223-3231
29. Kearon C, Crowther M, Hirsh J (2000) Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51:169-185
30. Akar N, Akar E, Dalgin G, Sozuoz A, Omurlu K, Cin S (1997) Frequency of Factor V (1691 GG→AA) mutation in Turkish population. Thromb Haemost 78:1527-1528